Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Drug development firm Sareum has reported a half-annual loss on ordinary activities for the six months ended 31 December 2020 of £0.55m.
It comes after the firm experienced a 2019 loss of £0.61m, however, the firm has welcomed positive product developments.
Cash at the period end was £1.30 million versus £1.80 million as of 30 June 2020 and £1.00 million as of 31 December 2019.
R&D Tax Credit of £0.13 million was received in January 2021, with the board focussing on the capital position of the company to ensure that the new products are adequately resourced
The development of TYK2/JAK1 inhibitors have been prioritised, and the company has welcomed substantial progress despite the challenges of the Covid-19 pandemic and has completed dose range-finding studies in two preclinical toxicology species.
Dr Tim Mitchell, CEO, commented: We continue to actively engage with potential partners with a view to securing commercial licences for our TYK2/JAK1 programmes. We will, as usual, keep shareholders updated in this regard as appropriate.